Tavilermide

Unassigned

New Medicines

Keratoconjunctivitis; sicca (or dry eye disease)

Information

New molecular entity
-
Mimetogen Pharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

First-in-class, small-molecule nerve growth factor peptidomimetic, highly selective for TrkA, the receptor of nerve growth factor (NGF). NGF is critical for the survival & differentiation of neurons and many other non-neuronal cell types.
Dry eyes is a common condition affecting up to a third of those aged over 65 years. It is 50% more common in women than in men [3].
Keratoconjunctivitis; sicca (or dry eye disease)
Topical